Auto Injectors Market Size , Share , Trends , Analysis and Forecasts To 2022
Global Auto Injectors Market is accounted for $ 1.10 billion in 2015 and is expected to reach $ 3.78 billion by 2022 growing at a CAGR of 19.42 %. As large number of patients are opting for self administered treatment and care there is a flawless increase in use of Auto Injectors . Moreover , the high prevailing patients of anaphylaxis had presented a huge demand for the market which seems as pertaining factor behind the market growth . At the same time high cost and need for utmost care are some of the factors hampering the market .
Download Sample Report @ https :// marketreportscenter . com / request-sample / 328749
Prefilled Syringes in primary drug container segment seems to be predominant in market segment because of the dramatic effect on the way injectable drugs are developed , prescribed and administered . Anaphylaxis in the therapeutic application segment will be dominant throughout the forecast period , as more people are allergic and nauseous . While North America being the largest market , Asia pacific hails as fastest growing because of channeling investments into China and India and improving consumer awareness through marketing campaigns .
Some of the major key players of the market are Unilife Corporation , Novartis International AG , Becton , Dickinson and Company , Antares Pharma , Inc ., Mylan , Inc ., Adamis Pharmaceuticals Corp , Hospira Inc , Scandinavian Health Limited ( SHL ) Group , Sanofi SA , Itelliject Inc , Pfizer , Inc ., Lincoln Medical Ltd , Ypsomed Holdings AG , ALK Abello , Teva Pharmaceuticals Ltd and Biogen Idec , Inc .
Devices Covered : Smart Autoinjectors Product Specific Autoinjectors Manual Injection Autoinjectors Disposable Autoinjectors Reusable Autoinjectors Variable Dose Autoinjectors Automated Injection Autoinjectors
Product Types Covered : Standardized Auto-injectors Customized Auto-injectors
Therapeutic Applications covered : Autoimmune Diseases Anaphylaxis Anticoagulants Neurology